PE20110593A1 - Anticuerpos multiespecificos - Google Patents

Anticuerpos multiespecificos

Info

Publication number
PE20110593A1
PE20110593A1 PE2011000442A PE2011000442A PE20110593A1 PE 20110593 A1 PE20110593 A1 PE 20110593A1 PE 2011000442 A PE2011000442 A PE 2011000442A PE 2011000442 A PE2011000442 A PE 2011000442A PE 20110593 A1 PE20110593 A1 PE 20110593A1
Authority
PE
Peru
Prior art keywords
hvr
sequence
antibody
seq
referred
Prior art date
Application number
PE2011000442A
Other languages
English (en)
Inventor
Jenny M Bostrom
Germaine Fuh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41399375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110593(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20110593A1 publication Critical patent/PE20110593A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

REFERIDA A UN ANTICUERPO AISLADO QUE COMPRENDE UNA SECUENCIA DE REGION HIPERVARIABLE (HVR) L1 QUE COMPRENDE LA SECUENCIA NIAKTISGY (SEQ ID NO:1), DONDE DICHO ANTICUERPO ENLAZA ESPECIFICAMENTE UN RECEPTOR DE CRECIMIENTO EPIDERMICO HUMANO 2 (HER2) Y UN FACTOR DE CRECIMIENTO ENDOTELIO VASCULAR (VEGF). DICHO ANTICUERPO COMPRENDE ADEMAS, UNA O MAS SECUENCIAS HVR TALES COMO (i) HVR-L2 QUE COMPRENDE UNA SECUENCIA WGSFLY (SEQ ID NO:4) I (ii) HVR-L3 QUE COMPRENDE LA SECUENCIA HYSSPP (SEQ ID NO:3). TAMBIEN ESTA REFERIDA A UN POLINUCLEOTIDO QUE CODIFICA UN ANTICUERPO, UN POLIPEPTIDO, UN VECTOR Y UNA CELULA HUESPED
PE2011000442A 2008-09-03 2009-09-01 Anticuerpos multiespecificos PE20110593A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19085608P 2008-09-03 2008-09-03

Publications (1)

Publication Number Publication Date
PE20110593A1 true PE20110593A1 (es) 2011-09-10

Family

ID=41399375

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014002488A PE20150222A1 (es) 2008-09-03 2009-09-01 Anticuerpos multiespecificos
PE2011000442A PE20110593A1 (es) 2008-09-03 2009-09-01 Anticuerpos multiespecificos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014002488A PE20150222A1 (es) 2008-09-03 2009-09-01 Anticuerpos multiespecificos

Country Status (19)

Country Link
US (3) US8193321B2 (es)
EP (1) EP2324061B1 (es)
JP (1) JP5796831B2 (es)
KR (1) KR101705911B1 (es)
CN (1) CN102143977B (es)
AR (1) AR073538A1 (es)
AU (1) AU2009288167B2 (es)
BR (1) BRPI0918648A2 (es)
CA (1) CA2734905A1 (es)
ES (1) ES2628108T3 (es)
IL (1) IL211349A0 (es)
MX (1) MX353984B (es)
PE (2) PE20150222A1 (es)
PH (1) PH12013502230A1 (es)
RU (1) RU2547596C2 (es)
SG (1) SG193851A1 (es)
TW (1) TWI487712B (es)
WO (1) WO2010027981A1 (es)
ZA (1) ZA201101970B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
JP5796831B2 (ja) 2008-09-03 2015-10-21 ジェネンテック， インコーポレイテッド 多重特異性抗体
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
EP3539988A3 (en) 2010-05-27 2019-12-04 Genmab A/S Monoclonal antibodies against her2
CN103443124A (zh) * 2011-01-17 2013-12-11 诺沃—诺迪斯克有限公司 Il-21配体
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN104024432B (zh) 2011-08-31 2017-02-22 基因泰克公司 诊断性标志物
KR101453516B1 (ko) 2011-09-20 2014-10-24 가톨릭대학교 산학협력단 항-ｖｅｇｆ 항체를 포함하는 자가면역질환 예방 및 치료용 조성물
JP2014531213A (ja) 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
US11142563B2 (en) 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
HRP20211641T1 (hr) 2012-07-13 2022-02-04 Roche Glycart Ag Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti
WO2014134169A1 (en) * 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
CN113278076A (zh) * 2013-11-11 2021-08-20 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
JP2015097496A (ja) * 2013-11-19 2015-05-28 国立大学法人 東京大学 Ｒｏｂｏ１に対する親和性を向上させた抗体及び高親和性抗体の分子設計方法
WO2015119841A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Role of il-23 and pd-1 in autoreactive immune response
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US10526391B2 (en) 2014-07-22 2020-01-07 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
JP6897952B2 (ja) * 2014-09-16 2021-07-07 国立大学法人東京海洋大学 濃縮された生着能をもつ未分化生殖細胞を用いた生殖細胞系列への分化誘導方法
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
AU2016312259B2 (en) 2015-08-26 2018-12-06 Bison Therapeutics Inc. Multispecific antibody platform and related methods
CN116987187A (zh) 2015-09-23 2023-11-03 豪夫迈·罗氏有限公司 抗-vegf抗体的优化的变体
GB201521447D0 (en) * 2015-12-04 2016-01-20 Ucb Biopharma Sprl De novo antibody design
MA46681A (fr) * 2016-01-28 2019-09-11 Janssen Biotech Inc Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
EP3634999A1 (en) * 2017-06-07 2020-04-15 Philogen S.p.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
CN107602702A (zh) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
CN115397866A (zh) 2020-03-31 2022-11-25 中外制药株式会社 靶向dll3的多特异性抗原结合分子及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
KR100254759B1 (ko) 1992-01-23 2000-05-01 플레믹 크리스티안 단량체 및 이량체 항체-단편 융합 단백질
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2411374C (en) 2000-06-29 2012-10-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
JP2002355074A (ja) * 2001-01-24 2002-12-10 Univ Tsukuba 腸管出血性病原性大腸菌ｏ１５７：ｈ７に特異的な核酸分子およびポリペプチド並びにこれらの使用方法
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2003018749A2 (en) 2001-08-22 2003-03-06 Shengfeng Li Compositions and methods for generating antigen-binding units
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
CA2526085A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-vegf antibodies
EP1703893B1 (en) 2003-12-23 2012-04-11 Genentech, Inc. Novel anti-il 13 antibodies and uses thereof
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
MX2007001638A (es) 2004-08-11 2009-02-12 Trubion Pharmaceuticals Inc Proteinas de fusion del dominio de unión.
CN101365486B (zh) 2006-01-04 2012-10-31 默克专利有限公司 使用抗egfr和抗her2抗体的联合治疗
NZ591252A (en) * 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
KR101710472B1 (ko) * 2007-11-30 2017-02-27 글락소 그룹 리미티드 항원-결합 작제물
JP5796831B2 (ja) 2008-09-03 2015-10-21 ジェネンテック， インコーポレイテッド 多重特異性抗体

Also Published As

Publication number Publication date
KR101705911B1 (ko) 2017-02-10
MX2011002389A (es) 2011-05-23
TW201011047A (en) 2010-03-16
IL211349A0 (en) 2011-05-31
MX353984B (es) 2017-11-27
JP2012501648A (ja) 2012-01-26
US20150315290A1 (en) 2015-11-05
TWI487712B (zh) 2015-06-11
US20100322946A1 (en) 2010-12-23
AR073538A1 (es) 2010-11-17
EP2324061A1 (en) 2011-05-25
WO2010027981A1 (en) 2010-03-11
KR20110081812A (ko) 2011-07-14
ZA201101970B (en) 2012-05-30
PH12013502230A1 (en) 2016-01-25
PE20150222A1 (es) 2015-03-02
AU2009288167A1 (en) 2010-03-11
US20110142852A1 (en) 2011-06-16
US9522960B2 (en) 2016-12-20
RU2011112324A (ru) 2012-10-10
RU2547596C2 (ru) 2015-04-10
JP5796831B2 (ja) 2015-10-21
SG193851A1 (en) 2013-10-30
EP2324061B1 (en) 2017-04-12
US8193321B2 (en) 2012-06-05
ES2628108T3 (es) 2017-08-01
CN102143977B (zh) 2014-08-06
AU2009288167B2 (en) 2015-10-22
US9017686B2 (en) 2015-04-28
CA2734905A1 (en) 2010-03-11
BRPI0918648A2 (pt) 2019-09-03
CN102143977A (zh) 2011-08-03

Similar Documents

Publication Publication Date Title
PE20110593A1 (es) Anticuerpos multiespecificos
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
AR078377A1 (es) Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2015142675A3 (en) Treatment of cancer using chimeric antigen receptor
PE20150605A1 (es) Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
CL2012000806A1 (es) Anticuerpo anti-guanililo ciclasa c (gcc); inmunoconjugado de dicho anticuerpo; celula, vector y metodo de produccion; composicion que comprende el anticuerpo, uso del anticuerpo o composicion para preparar un medicamento para tratar cancer, particularmente del sistema gastrointestinal.
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
EA035160B9 (ru) Антитела к st2 и их применение
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
UA111818C2 (uk) Антитіло проти csf-1r
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
NZ597692A (en) Anti-IGF antibodies
WO2010129895A3 (en) Cd133 epitopes
WO2011069019A3 (en) J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
SG178886A1 (en) Humanized anti-cdcp1 antibodies
AR075029A1 (es) Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed